139 related articles for article (PubMed ID: 38387891)
1. [Immune Reconstitution after BTKi Treatment in Chronic Lymphocytic Leukemia].
Wang YL; Tang PX; Chen KL; Guo GY; Long JL; Zou YQ; Liang HY; Xu ZS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):1-5. PubMed ID: 38387891
[TBL] [Abstract][Full Text] [Related]
2. Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence.
Davis JE; Sharpe C; Mason K; Tam CS; Koldej RM; Ritchie DS
J Transl Med; 2021 Nov; 19(1):473. PubMed ID: 34809665
[TBL] [Abstract][Full Text] [Related]
3. Real-world patterns and sequences of targeted therapy use in chronic lymphocytic leukemia and small lymphocytic lymphoma in the United States: a longitudinal study.
Huntington SF; Cheng WY; Sarpong EM; Leng S; Farooqui MZH; Agu US; Catillon M; Lejeune D; Downes N; Matay L; Duh MS; De Nigris E
Leuk Lymphoma; 2024 May; ():1-11. PubMed ID: 38696747
[TBL] [Abstract][Full Text] [Related]
4. BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL.
Mhibik M; Gaglione EM; Eik D; Kendall EK; Blackburn A; Keyvanfar K; Baptista MJ; Ahn IE; Sun C; Qi J; Rader C; Wiestner A
Blood; 2021 Nov; 138(19):1843-1854. PubMed ID: 34046681
[TBL] [Abstract][Full Text] [Related]
5. Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL.
Mhibik M; Wiestner A; Sun C
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31861854
[TBL] [Abstract][Full Text] [Related]
6. The role of Bruton's kinase inhibitors (BTKi) in accelerated Chronic Lymphocytic Leukemia (a-CLL): a case of successful response to acalabrutinib.
Catania G; Tavarozzi R; Pini GM; Borra T; Gandolfo C; Zacchi G; Pietrasanta D; Monaco F; Zanni M; Lettieri M; Rivela P; Zallio F; Ladetto M
J Basic Clin Physiol Pharmacol; 2023 May; 34(3):401-404. PubMed ID: 37040263
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of new-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia/small lymphocytic lymphoma: a systematic review and meta-analysis.
Yin S; Zheng X; Zhang W; Zhao H; Zhang R; Li W; Chen F
Ann Hematol; 2023 Oct; ():. PubMed ID: 37843620
[TBL] [Abstract][Full Text] [Related]
8. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
Kanagal-Shamanna R; Jain P; Patel KP; Routbort M; Bueso-Ramos C; Alhalouli T; Khoury JD; Luthra R; Ferrajoli A; Keating M; Jain N; Burger J; Estrov Z; Wierda W; Kantarjian HM; Medeiros LJ
Cancer; 2019 Feb; 125(4):559-574. PubMed ID: 30508305
[TBL] [Abstract][Full Text] [Related]
9. Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model.
Chen SS; Barrientos JC; Ferrer G; King-Richards M; Chen YJ; Ravichandran P; Ibrahim M; Kieso Y; Waters S; Kutok JL; Peluso M; Sharma S; Weaver DT; Pachter JA; Rai KR; Chiorazzi N
Clin Cancer Res; 2023 May; 29(10):1984-1995. PubMed ID: 37071496
[TBL] [Abstract][Full Text] [Related]
10. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Zou YX; Zhu HY; Li XT; Xia Y; Miao KR; Zhao SS; Wu YJ; Wang L; Xu W; Li JY
Hematol Oncol; 2019 Oct; 37(4):392-400. PubMed ID: 31420873
[TBL] [Abstract][Full Text] [Related]
11. Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis.
Muchtar E; Koehler AB; Johnson MJ; Rabe KG; Ding W; Call TG; Leis JF; Kenderian SS; Hayman SR; Wang Y; Hampel PJ; Holets MA; Darby HC; Slager SL; Kay NE; Miao C; Canniff J; Whitaker JA; Levin MJ; Schmid DS; Kennedy RB; Weinberg A; Parikh SA
Am J Hematol; 2022 Jan; 97(1):90-98. PubMed ID: 34699616
[TBL] [Abstract][Full Text] [Related]
12. IFN-alpha stimulates proliferation and cytokine secretion of CD40-stimulated B cell chronic lymphocytic leukemia cells in vitro.
Brass U; Tretter T; Schneller F; Schuler M; Huber C; Peschel C
J Interferon Cytokine Res; 1999 Apr; 19(4):335-43. PubMed ID: 10334384
[TBL] [Abstract][Full Text] [Related]
13. Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responses.
Manna A; Kellett T; Aulakh S; Lewis-Tuffin LJ; Dutta N; Knutson K; Chini E; Pinilla-Ibarz J; Lamanna N; Manochakian R; Malavasi F; Sher T; Chanan-Khan AA; Ailawadhi S; Paulus A
Blood Adv; 2020 May; 4(10):2143-2157. PubMed ID: 32421811
[TBL] [Abstract][Full Text] [Related]
14. Interruption of BTK inhibitor improves response to SARS-CoV-2 booster vaccination in patients with CLL.
Tomasulo E; Paul S; Mu R; Tian X; Chen J; Pleyer C; Wiestner A; Sun C
Leuk Lymphoma; 2023 Dec; 64(14):2306-2315. PubMed ID: 37732614
[TBL] [Abstract][Full Text] [Related]
15. BTK-independent regulation of calcium signalling downstream of the B-cell receptor in malignant B-cells.
Arthur R; Wathen A; Lemm EA; Stevenson FK; Forconi F; Linley AJ; Steele AJ; Packham G; Valle-Argos B
Cell Signal; 2022 Aug; 96():110358. PubMed ID: 35597428
[TBL] [Abstract][Full Text] [Related]
16. [Short-term curative efficacy of autologous cytokine induced killer cells combined with low-dose IL-2 regimen containing immune enhancement by thymic peptide in elderly patients with B-cell chronic lymphocytic leukemia].
Cai LL; Yang Y; Yang B; Zhu HL; Lu XC; Zhang WY; Yu RL; Chi XH; Wang Y; Dai HR; Han WD; Fan H; Li SX; Liu Y; Ran HH; Lin J; Tuo S; Tuo CW; Zhang F; Cao JP; Yao SQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Jun; 20(3):564-70. PubMed ID: 22739156
[TBL] [Abstract][Full Text] [Related]
17. BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.
Lin VS; Lew TE; Handunnetti SM; Blombery P; Nguyen T; Westerman DA; Kuss BJ; Tam CS; Roberts AW; Seymour JF; Anderson MA
Blood; 2020 Jun; 135(25):2266-2270. PubMed ID: 32244251
[TBL] [Abstract][Full Text] [Related]
18. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.
Fan F; Yoo HJ; Stock S; Wang L; Liu Y; Schubert ML; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
Int J Cancer; 2021 Jan; 148(2):419-428. PubMed ID: 32683672
[TBL] [Abstract][Full Text] [Related]
19. Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia.
Bennett R; Anderson MA; Seymour JF
J Hematol Oncol; 2023 Jul; 16(1):72. PubMed ID: 37422670
[TBL] [Abstract][Full Text] [Related]
20. Production of intracellular IL-2, TNF-alpha, and IFN-gamma by T cells in B-CLL.
Gallego A; Vargas JA; Castejón R; Citores MJ; Romero Y; Millán I; Durántez A
Cytometry B Clin Cytom; 2003 Nov; 56(1):23-9. PubMed ID: 14582134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]